...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Broker Meeting 23 Feb
13
Feb 28, 2017 08:40PM
4
Feb 28, 2017 11:29PM
3
Mar 01, 2017 12:12AM
3
Mar 01, 2017 12:26AM
4
Mar 01, 2017 02:28AM
1
Mar 01, 2017 08:48AM
3
Mar 01, 2017 09:45AM
1
Mar 01, 2017 09:47AM
4
Mar 01, 2017 11:00AM
1
Mar 01, 2017 11:45AM
2
Mar 01, 2017 11:59AM

Tada.....thanks for posting this info. VERY interesting.

SanFran....thanks for sharing my previous post. Saved me the work of digging it up. As you can see from that previous post on the ASSURE/SUSTAIN trials, most of the events that occured in the 5-point MACE screen WERE NOT the death, stroke, MI that are the more strict 3-point MACE.

Most, if not all, cardiovascular outcome trials are time to first event. Tada's statement was "There have been over 190 events and 129 patients have had events." If these 190 events are not only the 3-point variety, but also include other cardiovascular events, then it is impossible to interpret this current info in terms of number of first occurence 3-point MACE events. It is encouraging to hear them say that they are still on track for August 2017 or earlier to reach the 125 first occurence 3-point MACE events.

BearDownAZ

2
Mar 01, 2017 12:58PM
4
Mar 01, 2017 01:16PM
2
Mar 01, 2017 01:25PM
1
Mar 01, 2017 01:39PM
2
Mar 01, 2017 02:01PM
2
Mar 01, 2017 03:01PM
5
Mar 01, 2017 03:19PM
5
Mar 01, 2017 03:48PM

Mar 01, 2017 07:08PM
1
Mar 01, 2017 08:31PM
Share
New Message
Please login to post a reply